References
- Wyeth Europe Ltd MUK. Enbrel® summary of product characteristics. 2005
- Enbrel® (etanercept). Full prescribing information [package insert]. Immunex Corp, Thousand Oaks, CA 2006
- Raptiva® (efalizumab). Full prescribing information [package insert]. Genentech Inc, South San Francisco, CA 2005
- Gottlieb A. B., Matheson R. T., Lowe N., Krueger G. G., Kang S., Goffe B. S., et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627–32
- Leonardi C. L., Powers J. L., Matheson R. T., Goffe B. S., Zitnik R., Wang A., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014–22
- Papp K. A., Tyring S., Lahfa M., Prinz J., Griffiths C. E., Nakanishi A. M., et al. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304–12
- Gordon K. B., Papp K. A., Hamilton T. K., Walicke P. A., Dummer W., Li N., et al. Efalizumab for patients with moderate to severe plaque psoriasis: A randomized controlled trial. JAMA 2003; 290: 3073–80
- Lebwohl M., Tyring S. K., Hamilton T. K., Toth D., Glazer S., Tawfik N. H., et al. A novel targeted T‐cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004–13
- Leonardi C. L., Papp K. A., Gordon K. B., Menter A., Feldman S. R., Caro I., et al. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol 2005; 52(3 Pt 1): 425–33
- Papp K. A., Bressinck R., Fretzin S., Goffe B., Kempers S., Gordon K. B., et al. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial. Int J Dermatol 2006; 45: 605–14
- Dubertret L., Sterry W., Bos J. D., Chimenti S., Shumack S., Larsen C. G., et al. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate‐to‐severe plaque psoriasis: Results from a phase III international randomized, placebo‐controlled trial. Br J Dermatol 2006; 155: 170–81
- Van der H. D., Klareskog L., Rodriguez‐Valverde V., Codreanu C., Bolosiu H., Melo‐Gomes J., et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two‐year clinical and radiographic results from the TEMPO study, a double‐blind, randomized trial. Arthritis Rheum 2006; 54: 1063–74
- Taban M., Dupps W. J., Mandell B., Perez V. L. Etanercept (enbrel)‐associated inflammatory eye disease: Case report and review of the literature. Ocul Immunol Inflamm 2006; 14: 145–50
- Carey W., Glazer S., Gottlieb A. B., Lebwohl M., Leonardi C., Menter A., et al. Relapse, rebound, and psoriasis adverse events: An advisory group report. J Am Acad Dermatol 2006; 54(4 Suppl 1): S171–81